George T. Kannarkat

LRRK2 levels in immune cells are increased in Parkinson’s disease

Darcie A. Cook, George T. Kannarkat, Amarallys F. Cintron et al. · npj Parkinson s Disease · 2017 · 306 citations · Full text

Life Sciences, Immunology, Pathobiology +15

Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson’s disease: an observational and case–control study

George T. Kannarkat, D A Cook, Jianjun Chang et al. · npj Parkinson s Disease · 2015 · 163 citations · Full text

Life Sciences, Genetics, Immunology +16

Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice

Kathryn P. MacPherson, Pradoldej Sompol, George T. Kannarkat et al. · Neurobiology of Disease · 2017 · 155 citations · Full text

Life Sciences, Immunology, Neuroscience +17

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease

Lori N. Eidson, George T. Kannarkat, Christopher J. Barnum et al. · Journal of Neuroinflammation · 2017 · 105 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Critical Role of Regulator G-Protein Signaling 10 (RGS10) in Modulating Macrophage M1/M2 Activation

Jae‐Kyung Lee, Jaegwon Chung, George T. Kannarkat et al. · PLoS ONE · 2013 · 86 citations · Full text

Life Sciences, Cell Biology, Immunology +17